Oral urate oxidase promotes intestinal uric acid excretion for gout treatment. To enhance the adhesion and uric acid degradation efficiency of recombinant pig-baboon chimeric urate oxidase (PBC) in the intestine, this study fused the mucin-binding protein (MUB) fragments with PBC to construct fusion proteins N1 to N7. By comparing the effects of different MUB fragments on the mucin-binding activity of PBC, and further investigating the high-density fermentation, separation, purification, and enzymatic properties of N5, it was found that the mucin-binding activity of fusion proteins N1 to N7 was significantly improved. Among them, the fusion protein N5, which linked the MUB fragment RⅣ at the N-terminus, showed a nearly 41-fold increase in mucin-binding activity. Using high-density fermentation, ammonium sulfate precipitation, polyethyleneimine clarification, and anion exchange chromatography, the purity of N5 reached 98.7%, with a fermentation yield of 4.47 g/L. Additionally, the specific activity of N5(0.52 IU/mg) increased by 30% compared to PBC, with enhanced substrate affinity (K_m=14.29 μmol/L), and it remained stable under room temperature, alkaline conditions, and in the presence of common metal ions. This study provides a reference for the subsequent development of oral urate oxidase as a candidate drug.